Cargando…

Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells

Resistance to antiepidermal growth factor (EGFR) strategies is an emerging clinical problem. Using human colorectal cancer (CRC) cells, we evaluated the involvement of the insulin receptor isoform-A (InsR-A) in de novo resistance to gefitinib, an EGFR tyrosine kinase inhibitor. Challenging the EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, H E, Gee, J M W, Barrow, D, Tonge, D, Holloway, B, Nicholson, R I
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360620/ https://www.ncbi.nlm.nih.gov/pubmed/16819546 http://dx.doi.org/10.1038/sj.bjc.6603237

Ejemplares similares

Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines
por: Mahalingam, D, et al.
Publicado: (2009)

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
por: Yokoyama, H, et al.
Publicado: (2006)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients
por: Nishio, M, et al.
Publicado: (2005)

Selective inhibition of TNF-α-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib
por: Ueno, Y, et al.
Publicado: (2005)

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
por: Nutt, J E, et al.
Publicado: (2007)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo
por: Oikonomou, E, et al.
Publicado: (2007)

Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010)

Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
por: Sanchez, W Y, et al.
Publicado: (2013)

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells
por: Byron, S A, et al.
Publicado: (2006)

Targeting de novo lipogenesis as a novel approach in anti-cancer therapy
por: Stoiber, Katharina, et al.
Publicado: (2018)

Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
por: Cambien, B, et al.
Publicado: (2009)

Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells
por: Ammerpohl, O, et al.
Publicado: (2007)

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
por: Santoro, A, et al.
Publicado: (2010)

Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential
por: Rieger-Christ, K M, et al.
Publicado: (2005)

Metallothionein crypt-restricted immunopositivity indices (MTCRII) correlate with aberrant crypt foci (ACF) in mouse colon
por: Donnelly, E T, et al.
Publicado: (2005)

Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo
por: Nielsen, T O, et al.
Publicado: (2013)

CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver
por: Guillemot, E, et al.
Publicado: (2012)

Pharmacological targeting of NF-κB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells
por: Lagadec, P, et al.
Publicado: (2008)

Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells
por: Stein, U, et al.
Publicado: (2012)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

The retinoid anticancer signal: mechanisms of target gene regulation
por: Liu, T, et al.
Publicado: (2005)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells
por: McCloy, R A, et al.
Publicado: (2013)

Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma
por: Watanabe, M, et al.
Publicado: (2010)

An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer
por: O'Donnell, Charlotte, et al.
Publicado: (2016)

FAT1: a potential target for monoclonal antibody therapy in colon cancer
por: Pileri, Piero, et al.
Publicado: (2016)

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
por: Lesterhuis, W J, et al.
Publicado: (2010)

Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model
por: Bhardwaj, A, et al.
Publicado: (2014)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

‘1-8 interferon inducible gene family’: putative colon carcinoma-associated antigens
por: Tirosh, B, et al.
Publicado: (2007)

The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

Expression of V(1A) and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition
por: MacKinnon, A C, et al.
Publicado: (2005)

BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt
por: Pal, I, et al.
Publicado: (2014)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_smgihhqo6s5up42onp37up3bc8